Related Experiment Videos
UFT plus cisplatin for advanced gastric cancer
1Toyosu Hospital, Showa University, Tokyo, Japan.
Oncology (Williston Park, N.Y.)
|February 12, 1998
Summary
The UFTP regimen, combining tegafur and uracil (UFT) with cisplatin, demonstrated improved survival in gastrointestinal cancer models compared to standard UFTM chemotherapy. Further clinical studies are ongoing to optimize this promising treatment.
Area of Science:
- Oncology
- Gastrointestinal Cancer Research
- Pharmacology
Background:
- Advanced gastrointestinal cancer in Japan has relied on UFTM (UFT plus mitomycin) as standard chemotherapy.
- The experimental peritoneum model is crucial for evaluating novel cancer treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of the UFTP (tegafur and uracil [UFT] plus cisplatin) regimen.
- To compare the UFTP regimen against the established UFTM regimen for advanced gastrointestinal cancer.
- To explore the potential clinical benefits and survival advantages of UFTP.
Main Methods:
- Laboratory study utilizing an experimental peritoneum model of gastrointestinal cancer.
- Pilot clinical study to assess antitumor effects and survival impact.
- Phase II study to optimize UFTP administration schedule and reduce toxicity.
Main Results:
- The UFTP regimen showed a survival benefit in the experimental peritoneum model compared to UFTM.
- Pilot clinical studies indicated excellent antitumor effects and potential survival improvement with UFTP.
- Current phase II study aims to maintain benefits while reducing toxicity.
Conclusions:
- The UFTP regimen presents a promising alternative to UFTM for advanced gastrointestinal cancer.
- Clinical benefits and improved survival are anticipated with the UFTP regimen.
- Ongoing research focuses on refining UFTP administration for optimal patient outcomes.